Literature DB >> 15542640

Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate.

Stéphane Biacchesi1, Mario H Skiadopoulos, Lijuan Yang, Elaine W Lamirande, Kim C Tran, Brian R Murphy, Peter L Collins, Ursula J Buchholz.   

Abstract

Human metapneumovirus (HMPV) has recently been identified as a significant cause of serious respiratory tract disease in humans. In particular, the emerging information on the contribution of HMPV to pediatric respiratory tract disease suggests that it will be important to develop a vaccine against this virus for use in conjunction with those being developed for human respiratory syncytial virus and the human parainfluenza viruses. A recently described reverse genetic system (S. Biacchesi, M. H. Skiadopoulos, K. C. Tran, B. R. Murphy, P. L. Collins, and U. J. Buchholz, Virology 321:247-259, 2004) was used to generate recombinant HMPVs (rHMPVs) that lack the G gene, the SH gene, or both. The DeltaSH, DeltaG, and DeltaSH/G deletion mutants were readily recovered and were found to replicate efficiently during multicycle growth in cell culture. Thus, the SH and G proteins are not essential for growth in cell culture. Apart from the absence of the deleted protein(s), the virions produced by the gene deletion mutants were similar by protein yield and gel electrophoresis protein profile to wild-type HMPV. When administered intranasally to hamsters, the DeltaG and DeltaSH/G mutants replicated in both the upper and lower respiratory tracts, showing that HMPV containing F as the sole viral surface protein is competent for replication in vivo. However, both viruses were at least 40-fold and 600-fold restricted in replication in the lower and upper respiratory tract, respectively, compared to wild-type rHMPV. They also induced high titers of HMPV-neutralizing serum antibodies and conferred complete protection against replication of wild-type HMPV challenge virus in the lungs. Surprisingly, G is dispensable for protection, and the DeltaG and DeltaSH/G viruses represent promising vaccine candidates. In contrast, DeltaSH replicated somewhat more efficiently in hamster lungs compared to wild-type rHMPV (20-fold increase on day 5 postinfection). This indicates that SH is completely dispensable in vivo and that its deletion does not confer an attenuating effect, at least in this rodent model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542640      PMCID: PMC525014          DOI: 10.1128/JVI.78.23.12877-12887.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

Review 1.  Human metapneumovirus: a not so new virus.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Octavio Ramilo
Journal:  Pediatr Infect Dis J       Date:  2004-01       Impact factor: 2.129

Review 2.  Viroporins.

Authors:  Maria Eugenia Gonzalez; Luis Carrasco
Journal:  FEBS Lett       Date:  2003-09-18       Impact factor: 4.124

3.  Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.

Authors:  Roderick S Tang; Jeanne H Schickli; Mia MacPhail; Fiona Fernandes; Leenas Bicha; Joshua Spaete; Ron A M Fouchier; Albert D M E Osterhaus; Richard Spaete; Aurelia A Haller
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness.

Authors:  Mario H Skiadopoulos; Stéphane Biacchesi; Ursula J Buchholz; Jeffrey M Riggs; Sonja R Surman; Emerito Amaro-Carambot; Josephine M McAuliffe; William R Elkins; Marisa St Claire; Peter L Collins; Brian R Murphy
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 5.  Clinical impact and diagnosis of human metapneumovirus infection.

Authors:  Bernadette G van den Hoogen; D M E Osterhaus; Ron A M Fouchier
Journal:  Pediatr Infect Dis J       Date:  2004-01       Impact factor: 2.129

6.  Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes.

Authors:  Stéphane Biacchesi; Mario H Skiadopoulos; Kim C Tran; Brian R Murphy; Peter L Collins; Ursula J Buchholz
Journal:  Virology       Date:  2004-04-10       Impact factor: 3.616

7.  Sequence polymorphism of the predicted human metapneumovirus G glycoprotein.

Authors:  Teresa C T Peret; Yacine Abed; Larry J Anderson; Dean D Erdman; Guy Boivin
Journal:  J Gen Virol       Date:  2004-03       Impact factor: 3.891

8.  Modeling the structure of the respiratory syncytial virus small hydrophobic protein by silent-mutation analysis of global searching molecular dynamics.

Authors:  Uzi Kochva; Hadas Leonov; Isaiah T Arkin
Journal:  Protein Sci       Date:  2003-12       Impact factor: 6.725

9.  Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design.

Authors:  Mia MacPhail; Jeanne H Schickli; Roderick S Tang; Jasmine Kaur; Christopher Robinson; Ron A M Fouchier; Albert D M E Osterhaus; Richard R Spaete; Aurelia A Haller
Journal:  J Gen Virol       Date:  2004-06       Impact factor: 3.891

10.  Human metapneumovirus: a new player among respiratory viruses.

Authors:  Marie-Eve Hamelin; Yacine Abed; Guy Boivin
Journal:  Clin Infect Dis       Date:  2004-03-15       Impact factor: 9.079

View more
  105 in total

1.  Human metapneumovirus glycoprotein G inhibits TLR4-dependent signaling in monocyte-derived dendritic cells.

Authors:  Deepthi Kolli; Xiaoyong Bao; Tianshuang Liu; Chao Hong; Tian Wang; Roberto P Garofalo; Antonella Casola
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

2.  Residues of the human metapneumovirus fusion (F) protein critical for its strain-related fusion phenotype: implications for the virus replication cycle.

Authors:  Vicente Mas; Sander Herfst; Albert D M E Osterhaus; Ron A M Fouchier; José A Melero
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

3.  Characterization of human metapneumovirus F protein-promoted membrane fusion: critical roles for proteolytic processing and low pH.

Authors:  Rachel M Schowalter; Stacy E Smith; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 4.  New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.

Authors:  Peter L Collins; Brian R Murphy
Journal:  Proc Am Thorac Soc       Date:  2005

Review 5.  Recent vaccine development for human metapneumovirus.

Authors:  J Ren; T Phan; X Bao
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

6.  Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice.

Authors:  Karen A Herd; Suresh Mahalingam; Ian M Mackay; Michael Nissen; Theo P Sloots; Robert W Tindle
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

7.  Insertion of the two cleavage sites of the respiratory syncytial virus fusion protein in Sendai virus fusion protein leads to enhanced cell-cell fusion and a decreased dependency on the HN attachment protein for activity.

Authors:  Joanna Rawling; Blanca García-Barreno; José A Melero
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

8.  Human metapneumovirus G protein is highly conserved within but not between genetic lineages.

Authors:  Chin-Fen Yang; Chiaoyin K Wang; Sharon J Tollefson; Linda D Lintao; Alexis Liem; Marla Chu; John V Williams
Journal:  Arch Virol       Date:  2013-02-06       Impact factor: 2.574

9.  Complete sequence of the RNA genome of pneumonia virus of mice (PVM).

Authors:  Christine D Krempl; Elaine W Lamirande; Peter L Collins
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

Review 10.  Molecular mechanisms driving respiratory syncytial virus assembly.

Authors:  Fyza Y Shaikh; James E Crowe
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.